HDR Gateway logo
HDR Gateway logo

Bookmarks

Prevalence, prediction, and health outcomes of cardioprotective medication reduction in the older UK population

Safe People

Organisation name

University of Oxford

Organisation sector

Academic Institute

Applicant name(s)

James Sheppard - Chief Investigator - University of OxfordRik van der Veen - Corresponding Applicant - University of OxfordConstantinos Koshiaris - Collaborator - University of OxfordKamal Mahtani - Collaborator - University of OxfordRichard Hobbs - Collaborator - University of OxfordRichard McManus - Collaborator - University of Oxford

Safe Projects

Project ID

CPRD05

Lay summary

Life expectancy has increased in recent decades, driven by advances in medical sciences. Diseases which would drastically lower life expectancy previously are now successfully treated with multiple drugs. Older people tend to accumulate more life-long conditions and therefore take more prescription drugs. However, taking multiple drugs may not but without risk. Some can cause side effects which might be serious. These include drugs used to prevent heart disease, such as those used to lower blood pressure and cholesterol. One way to prevent possible harm could be to reduce the number of drugs prescribed in patients where the benefits of continued treatment may be outweighed by the harms. However, the harms and benefits of reducing these drugs in patients are currently unknown.

Technical summary

Background

Latest approval date

28/05/2021

Safe Data

Dataset(s) name

HES Admitted Patient Care

ONS Death Registration Data

Patient Level Index of Multiple Deprivation

Safe Setting

Access type

Release